Current Clinical Trials
Thoracic and lung specialized cancer research program
To inquire about ongoing thoracic and lung cancer clinical trials, please reach the clinical research team on 01-350000 Ext: 5110, 7804 or 7803
Ongoing thoracic and lung cancer clinical research projects:
Lung – Respiratory cancers
- A phase III, open label multi-center trial of avelumab (MSB0010718C) versus platinum based doublet as a first-line treatment of recurrent or stage IV PD-L1+ non-small cell lung cancer.
- CINC280A2201: Phase II multicenter, three-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR with type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease
- CA209227: An open label, randomized, phase 3 trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in subjects with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC)
- BO40336: A phase III, open-label, randomized study to evaluate the efficacy and safety of adjuvant alectinib versus adjuvant platinum-based chemotherapy in patients with completely resected stage ib (tumors >=4 cm) to stage IIIa anaplastic lymphoma kinase-positive non-small cell lung cancer
QUICK LINKS
